Bormioli Pharma, a global leader that works with customers to provide comprehensive packaging solutions for injectable drugs, today announced robust growth of its North American business in 2022 with revenue growth of more than 40% year-on-year. Growth in North America was offset by strong sales increases in the company’s global markets, reflecting Bormioli’s multi-million dollar investments to expand its capabilities as a total packaging solutions provider for injectable drugs.
Photo credit: Bormioli Pharma
Bormioli Pharma was founded in 1825 as Bormioli Rocco, a manufacturer of glass containers and has a long history of innovation in the packaging industry. Today, as a strategic partner to many leading drug manufacturers, the company serves the pharmaceutical and biopharmaceutical markets with complete packaging solutions, including glass and plastic bottles, plastic and aluminum closures and accessories.
The US glass bottle market is grappling with ongoing supply issues for injectable glass packaging due to the ongoing impact of the COVID-19 pandemic and resulting supply chain disruptions. Bormioli strives to offer a total solution with its ever expanding capabilities in high quality glass vials, rubber stoppers and aluminum closures. In particular, the company has invested in strengthening its tubular glass vial capabilities with advanced machinery, while also modernizing its molded glass platform and expanding clean room capabilities for rubber stopper manufacturing. These developments have been aided by recent acquisitions which enable Bormioli to manufacture rubber and aluminum closures and tubular glass vials reliably and efficiently.
We have been at the forefront of molded glass manufacturing for nearly 200 years and have now extended those capabilities to tubular glass vials for injectable drugs and vaccines.
Our proud history matches our current passion for innovation in providing innovative total packaging solutions to drug manufacturers. As a single supplier of all components of the injection medication kit, we are able to offer a wide range of cost-effective, flexible solutions tailored to the needs of the customer, while pursuing an ambitious agenda to significantly improve the sustainability of all our activities. Our multi-faceted commitment is driven by two key factors – the supply chain issues stemming from the continued shortage of glass packaging for injectable medicines and the stark reminders of the inevitable dangers of ongoing climate change.”
Andrea Lodetti, Chief Executive Officer, Bormioli Pharma.
Bormioli Pharma’s products help ensure maximum drug stability by protecting drugs from spoilage, prolonging drug stability and enabling accurate dosing, thereby contributing to the health of those being treated.
In anticipation of the upcoming 200thth On the anniversary Bormioli Pharma launched “50-in-5”, an ambitious program to achieve 50% sustainable raw materials in its pharmaceutical packaging production by 2025. “50-in-5” is a project that affects the entire production area. To achieve this ambitious goal, the company has strengthened and expanded its industrial platform with investments of more than 50 million euros so far, which will be complemented by similar investments over the next three years. Strategies include increasing the percentage of recycled materials throughout the production process and adopting carbon capture and other environmentally friendly materials for container closure components and gaskets.
To learn more about this initiative and Bormioli’s comprehensive packaging solutions, please contact Bormioli executives at DCAT Week 2023 or contact a dedicated local US sales representative at dcat@bormiolipharma.com.
